First-line treatment with prednisolone (PSL) plus calcineurin inhibitor (CNI) has resulted in significantly better progression-free survival (PFS) in patients with aminoacyl-tRNA synthetase antibody–positive polymyositis/dermatomyositis-associated interstitial lung disease (ARS-PM/DM-ILD) compared with PSL monotherapy, according to a recent study. However, no significant difference is seen in terms of long-term survival among patients.
Patients with giant cell arteritis (GCA) receiving glucocorticoid (GC) plus methotrexate (MTX) have a nearly twofold lower rate of subsequent relapse compared to those taking GC alone, a study has shown.
In pregnant women with well-controlled rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), tumour necrosis factor inhibitor (TNFi) may be discontinued before gestational week 20 without the risk of disease worsening, as shown in a study.
Biweekly treatment with pegloticase yields favourable effects on systolic and diastolic blood pressure as well as mean arterial pressure in gout patients who maintain a persistently low serum urate, and these effects are independent of changes in renal function, according to a posthoc analysis of two trials.
In a US-based registry, only a few patients with psoriatic arthritis (PsA) on tumour necrosis factor inhibitor (TNFi) have achieved remission using the Clinical Disease Activity Index (CDAI) criteria, according to a new study, noting that female sex, obesity, comorbidities and education are associated with achieving remission.
Tofacitinib yields clinical and radiographic improvements in rheumatoid arthritis (RA) patients with inadequate response to methotrexate, and such improvements are sustained for up to 24 months without new safety signals, according to the results of the phase III ORAL* Scan trial.
Recent continuous use of methotrexate (MTX) is associated with a 20-percent decrease in cardiovascular events (CVE) in patients with early-onset rheumatoid arthritis (RA), a recent study has shown. In addition, greater MTX use in the first year of cohort entry appears to lower the risk of CVE.
Use of atorvastatin in patients with rheumatoid arthritis is safe and leads to substantial reductions in low-density lipoprotein cholesterol, which translates to a 40-percent decrease in the risk of cardiovascular events, according to data from the TRACE RA trial.
Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
Cabozantinib is not better than mitoxantrone-prednisone at relieving pain in patients with metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastasis, a recent study suggests.